drugset
drugset / Trial / NCT02971683

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

NCT02971683 ↗

Phase 3 Completed 149 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Timeline

Start
2017-05-04
Primary completion
2020-07-27
Completion
2022-08-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified — Subcutaneous

Indications

dermatomyositis immune-mediated necrotizing myopathy juvenile idiopathic inflammatory myopathy overlap myositis